Roche Reports the US FDA’s Approval of Ocrevus Zunovo for Treating Relapse and Progressive Multiple Sclerosis
Shots:
- The US FDA has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq), a twice-a-year, 10-minute SC injection, to treat relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS)
- The approval was supported by the pivotal P-III (OCARINA) study assessing the PK, safety, clinical & radiological efficacy of the Ocrevus SC vs IV in patients (n=236) with RMS or PPMS
- The study depicted that SC Ocrevus Zunovo had similar blood levels, safety & efficacy to the IV form in RMS & PPMS. It suppressed relapse activity & MRI lesions by 97% over 48wks. Over 92% of them preferred SC formulation
Ref: Roche | Image: Roche
Related News:- Roche’s Ocrevus SC (Ocrelizumab) Receives the EC’s Approval to Treat Multiple Sclerosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
